Alcon Inc. (SWX:ALC)
72.02
+0.26 (0.36%)
Jun 6, 2025, 5:38 PM CET
Alcon Revenue
Alcon had revenue of $2.47B USD in the quarter ending March 31, 2025, with 0.57% growth. This brings the company's revenue in the last twelve months to $9.93B, up 3.80% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm)
$9.93B
Revenue Growth
+3.80%
P/S Ratio
4.07
Revenue / Employee
$387.71K
Employees
25,599
Market Cap
35.70B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 47.05B |
Lonza Group AG | 6.57B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Alcon News
- 3 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Business Wire
- 8 days ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
- 9 days ago - US FDA approves Alcon's new dry-eye drug - Reuters
- 9 days ago - Alcon up 4% as FDA approves Tryptyr drops for dry eye - Seeking Alpha
- 9 days ago - Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - Business Wire
- 11 days ago - Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - GlobeNewsWire
- 23 days ago - American Eagle Slumps After Weak Q1 Preview, Analyst Cuts Forecasts On Demand Concerns - Benzinga
- 23 days ago - Alcon updates 2025 sales growth target to 6%-7% driven by new product launches and tariff mitigation - Seeking Alpha